Trial Profile
A Phase III Randomized, Double Blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Capecitabine
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms RESILIENCE
- Sponsors Bayer; Bayer HealthCare
- 25 Nov 2017 This trial has been completed in Germany (30 Oct 2017).
- 14 Nov 2017 Status changed from active, no longer recruiting to completed.
- 09 Jul 2017 Planned End Date changed from 30 Jun 2017 to 30 Sep 2017.